| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Renuka Ramanathan | |
| Kim Woodrow | |||
| P2860 | cites work | Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 | Q22010648 |
| Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000 | Q22306086 | ||
| Roles of antimicrobial peptides such as defensins in innate and adaptive immunity | Q24675023 | ||
| Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens | Q28206241 | ||
| The CC chemokine CCL20 and its receptor CCR6. | Q30333360 | ||
| Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. | Q30468622 | ||
| Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus | Q30491417 | ||
| Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. | Q30542085 | ||
| IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections | Q30585914 | ||
| Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? | Q31963533 | ||
| Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. | Q33217285 | ||
| Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines | Q33712280 | ||
| Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. | Q33944566 | ||
| Collaboration of epithelial cells with organized mucosal lymphoid tissues. | Q33955758 | ||
| Mucosal immunoglobulins | Q33988943 | ||
| Chemokines: immunology's high impact factors | Q34139595 | ||
| Diffusion of macromolecules and virus-like particles in human cervical mucus | Q34176484 | ||
| Mucoadhesive nanoparticulate systems for peptide drug delivery | Q34184353 | ||
| Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees | Q48036802 | ||
| Directed cell migration via chemoattractants released from degradable microspheres. | Q51528715 | ||
| PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. | Q53076908 | ||
| Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. | Q53399961 | ||
| Mucoadhesive systems in oral drug delivery | Q57360150 | ||
| Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa | Q57362811 | ||
| Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro | Q58035187 | ||
| Mucin Genes Expressed by Human Female Reproductive Tract Epithelia1 | Q60686918 | ||
| Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints | Q62517483 | ||
| Transitional Changes in the Surface Epithelium of the Cycling Mouse Vagina, Cervix and Uterus: Scanning Electron Microscopic Studies | Q67017730 | ||
| Endocervical pH measured in vivo through the normal menstrual cycle | Q71418755 | ||
| CpG DNA as mucosal adjuvant | Q73042328 | ||
| The scope and potential of vaginal drug delivery | Q73120421 | ||
| Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle | Q74335025 | ||
| Mucosal vaccination strategies for women | Q74659489 | ||
| Vaginal pH neutralization by semen as a cofactor of HIV transmission | Q77687332 | ||
| Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina | Q81312029 | ||
| Novel fusogenic liposomes for fluorescent cell labeling and membrane modification | Q83033203 | ||
| Effects of MIP-1α, MIP-3α, and MIP-3β on the Induction of HIV Gag-specific Immune Response with DNA Vaccines | Q95781067 | ||
| Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery | Q39681409 | ||
| Leukocytes migrate through three-dimensional gels of midcycle cervical mucus | Q41462425 | ||
| Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats | Q41888204 | ||
| Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites | Q42971765 | ||
| Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. | Q44992359 | ||
| Mucosal dendritic cells in immunity and inflammation | Q45053078 | ||
| Nanoparticles target distinct dendritic cell populations according to their size | Q45732404 | ||
| Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. | Q46941018 | ||
| Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors | Q47409832 | ||
| Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier | Q47877358 | ||
| Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells | Q34211233 | ||
| Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection | Q34228659 | ||
| Neonatal Fc receptor: from immunity to therapeutics | Q34268801 | ||
| Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. | Q34343298 | ||
| Liposomes as vaccine delivery systems: a review of the recent advances | Q34418761 | ||
| Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development | Q34446194 | ||
| Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue | Q34471984 | ||
| Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. | Q34568549 | ||
| Mucosal dendritic cells | Q34611254 | ||
| Nanoparticles in medicine: therapeutic applications and developments | Q34655287 | ||
| Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection | Q34693822 | ||
| Lipopeptide vaccines--yesterday, today, and tomorrow | Q34749774 | ||
| Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 | ||
| NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2 | Q34822004 | ||
| Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells | Q34887778 | ||
| Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists | Q34942985 | ||
| Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections | Q34982527 | ||
| Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense | Q35001584 | ||
| CpG DNA as a vaccine adjuvant. | Q35025722 | ||
| Vaginal immunization to elicit primary T-cell activation and dissemination | Q35069383 | ||
| A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection | Q35274924 | ||
| Factors affecting vaginal pH levels among female adolescents attending genitourinary medicine clinics | Q35532024 | ||
| Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women | Q35545581 | ||
| Nanoparticle PEGylation for imaging and therapy | Q35553193 | ||
| In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery | Q35563449 | ||
| Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells | Q35634313 | ||
| The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. | Q35675023 | ||
| Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy | Q35679856 | ||
| Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. | Q35830147 | ||
| Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | Q35878909 | ||
| Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines | Q35953762 | ||
| Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion | Q36032477 | ||
| Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection | Q36079848 | ||
| The rise and rise of drug delivery | Q36111904 | ||
| HIV/AIDS in women: an expanding epidemic | Q36157693 | ||
| Unique features of antiviral immune system of the vaginal mucosa | Q36177229 | ||
| Vaginal epithelial dendritic cells renew from bone marrow precursors | Q36277209 | ||
| Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine | Q36368440 | ||
| Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. | Q36368813 | ||
| Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2 | Q36370493 | ||
| Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens | Q36395541 | ||
| A vaccine strategy that protects against genital herpes by establishing local memory T cells | Q36403540 | ||
| Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines | Q36627931 | ||
| Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis | Q36798974 | ||
| Antiinfective applications of toll-like receptor 9 agonists | Q36868322 | ||
| Antiviral immune responses in the genital tract: clues for vaccines | Q36918159 | ||
| Targeted polymeric therapeutic nanoparticles: design, development and clinical translation | Q36934007 | ||
| CCR6 as a possible therapeutic target in psoriasis | Q36980670 | ||
| Setting the stage: host invasion by HIV. | Q36983857 | ||
| WHO global strategy for the prevention and control of sexually transmitted infections: time for action. | Q37006183 | ||
| Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. | Q37125727 | ||
| Vaginal drug delivery systems for HIV prevention | Q37149107 | ||
| Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier | Q37153146 | ||
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Q37153923 | ||
| Dendritic cells and macrophages in the genitourinary tract | Q37197967 | ||
| Genital delivery of virus-like particle and pseudovirus-based vaccines | Q37205981 | ||
| Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA | Q37219628 | ||
| Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus | Q37280337 | ||
| Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens | Q37280601 | ||
| Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. | Q37334251 | ||
| Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections | Q37334286 | ||
| Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination | Q37603557 | ||
| CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides | Q37746413 | ||
| CCR6 as a mediator of immunity in the lung and gut. | Q37849901 | ||
| Female genital tract immunity: distinct immunological challenges for vaccine development | Q37966494 | ||
| Nanoparticle vaccines | Q38167942 | ||
| Reinforcement of epithelial cell adhesion to basement membrane by a bacterial pathogen as a new infectious stratagem | Q39617000 | ||
| pH-sensitive Eudragit nanoparticles for mucosal drug delivery | Q39640640 | ||
| P433 | issue | 1 | |
| P921 | main subject | sexually transmitted infection | Q12198 |
| sexual transmission | Q45349134 | ||
| P304 | page(s) | 107-122 | |
| P577 | publication date | 2015-07-07 | |
| P1433 | published in | Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology | Q24056192 |
| P1476 | title | Engineering immunity in the mucosal niche against sexually transmitted infections | |
| P478 | volume | 8 |
Search more.